Ordinary Medicine: Extraordinary Treatments, Longer Lives, and Where to Draw the Line
Sharon R. Kaufman is Chair of the Department of Anthropology, History and Social Medicine at the University of California, San Francisco. She is the author of …And a Time to Die: How American Hospitals Shape the End of Life.
The Medical-Industrial Complex II: Access, Industry, and the Clinical Trials Phenomenon
2015. "The Medical-Industrial Complex II: Access, Industry, and the Clinical Trials Phenomenon", Ordinary Medicine: Extraordinary Treatments, Longer Lives, and Where to Draw the Line, Sharon R. Kaufman
Download citation file:
This chapter shows how evidence from clinical trials emerges, how those findings determine insurance reimbursement patterns and then treatment standards, and how those organize the work of doctors. It ends with a look at the specter that hangs over these engines of innovation and evidence: the fact that the pharmaceutical and biotech industries and the for-profit market for technologies have a growing impact on shaping research agendas and thus on shaping treatments.